Replimune Group REPL Unrecognized compensation cost related to non-vested awards

Unrecognized compensation cost related to non-vested awards at other companies

ModernaMRNA

——

Operating income-$71.9M-8.9%

Net income-$70.9M-6.9%

EPS (diluted)-$0.77+2.5%

Cash & equivalents$124.7M-28.3%

Total debt$79.2M+0.5%

Total equity$210.5M-56.4%

Total assets$333.6M-44.7%

Operating cash flow-$66.0M-30.1%

CapEx$135.0K-92.5%

Free cash flow-$66.1M-25.9%

Market cap$930.59M+28.6%

Enterprise value$885.15M+28.3%

Return on equity-90.9%+362pp

Debt / equity0.4×+0.2×

Current ratio5.6×-5.8×

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Replimune Group's unrecognized compensation cost related to non-vested awards?: Replimune Group (REPL) reported unrecognized compensation cost related to non-vested awards of $41.5M in Q4 2025.
How has Replimune Group's unrecognized compensation cost related to non-vested awards changed year-over-year?: Replimune Group's unrecognized compensation cost related to non-vested awards increased by 40.7% year-over-year, from $29.5M to $41.5M.